DiaMedica Therapeutics (DMAC) Assets Average (2019 - 2026)

DiaMedica Therapeutics' Assets Average history runs 8 years deep, the most recent figure standing at $57.2 million for Q1 2026.

• On a quarterly basis, Assets Average rose 34.37% year-over-year to $57.2 million in Q1 2026; TTM through Mar 2026 was $57.2 million, a 34.37% increase from a year earlier, with the FY2025 full-year figure at $53.9 million, up 7.17% from the prior year.
• Assets Average slipped to $57.2 million in Q1 2026 per DMAC's latest filing, from $59.2 million in the prior quarter.
• Across five years, Assets Average topped out at $60.1 million in Q3 2023 and bottomed at $32.3 million in Q1 2023.
• The 5-year median for Assets Average is $46.1 million (2023), against an average of $47.1 million.
• Across the five-year window, Assets Average soared 76.61% in 2022 and tumbled 33.71% in 2025, its largest moves.
• Year by year, Assets Average stood at $35.7 million in 2022, then soared by 57.2% to $56.1 million in 2023, then decreased by 11.96% to $49.4 million in 2024, then gained by 19.77% to $59.2 million in 2025, then dropped by 3.35% to $57.2 million in 2026.
• Per Business Quant, the three latest DMAC Assets Average figures stand at $57.2 million (Q1 2026), $59.2 million (Q4 2025), and $44.3 million (Q3 2025).